Study of a new drug for her2-positive solid tumors
Part of Cancer, Digestive system, Lungs & breathing, Skin clinical trials.
This study tests an investigational drug called KJ015 for people with HER2-positive solid tumors (cancer that has a specific protein on its surface). The goal is to see if the drug is safe and effective in treating your type of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- Your cancer must have gotten worse during or after your last treatment
- Your tumor must be HER2-positive (a protein that helps cancer cells grow)
- You must be well enough to care for yourself (ECOG 0–1 for dose escalation, 0–2 for some other parts)
- No untreated or uncontrolled brain or spinal cord tumors
- Your blood counts and organ function must be within required limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests IKS014 to see how safe it is and how well it works in advanced solid tumors that have HER2. You may be eligible if your tumor is HER2-positive (including certain “low HER2” types) and your body’s blood counts and organ function are strong enough.
This trial compares a new experimental drug, JSKN003, to standard treatments chosen by your doctor for advanced breast cancer that tests as HER2-low (IHC 1+ or 2+ but not amplified). It's for people whose cancer has spread or can't be removed and who have already had one or two lines of chemotherapy.
This trial tests a new experimental drug for people with advanced solid tumors that have not responded to standard treatments. It aims to find a safe dose and see if the drug can shrink tumors.
This trial tests a new combination drug (JSKN016) for people with HER2-negative breast cancer that has spread or cannot be removed. It is for those who have not yet had advanced-stage treatment (except hormone therapy) and may offer a new option.
This trial tests a new drug called SSGJ-705, given alone or with other treatments, for advanced cancers that have a specific protein (HER2) on their surface. It is for people with lung, breast, or stomach cancer that has spread and hasn't gotten better with other treatments.
This trial compares a new targeted therapy (JSKN003) against Kadcyla (T-DM1) for people with HER2-positive breast cancer that has advanced or spread. Both drugs work by attaching a chemotherapy directly to HER2-positive cancer cells, and the study aims to see if the new drug works better or has fewer side effects.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.